At a glance
ClinicalIndex Comparison Record- ✓Advanced HCC with GPC3 protein expression
- ✓Life expectancy greater than 12 weeks
- ✓Child-Pugh-Turcotte score less than 7
- ✓Adequate heart, lung, liver, kidney function
- ✕Prior gene therapy
- ✕Tumor size greater than 25 cm
- ✕Severe viral infection (HBV, HCV, HIV)
- ✕Known HIV positivity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating GPC3 and/or TGFβ targeting CAR-T cells for Hepatocellular Carcinoma and 5 related conditions. Currently recruiting, targeting 30 participants across 2 sites.
Detailed Summary
The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.
Study Details
Timeline
Interventions
Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.